Arbutus Biopharma Corporation · NASDAQ:ABUS

Arbutus Biopharma — Investor Presentation (January 2025)

22 slides from Arbutus Biopharma's investor presentation, Jan 13, 2025

  1. Slide 1: Corporate Presentation

    NASDAQ: ABUS www.arbutusbio.com January 13, 2025 Corporate Presentation © 2025 Arbutus Biopharma, Inc.

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo

  3. Slide 3: Arbutus Biopharma (ABUS) Overview

    Arbutus Biopharma (ABUS) Overview ~250M 1 people have cHBV with current treatment options for most patients limited to life - long suppressive therapy, representing a need for a finite curative regimen. HBV Represents a Large Commercial Opportunity ` Phase 2a clinical trial data with imdusiran shows

  4. Slide 4: Strategy for Value Creation

    PHASE 1 PHASE 2 PHASE 3 Strategy for Value Creation Develop a combination therapy that includes antivirals and immunomodulators to provide a finite, curative treatment for people with chronic HBV Imdusiran (IDR) RNAi Therapeutic (Subcutaneous) AB - 101 PD - L1 Inhibitor (Oral) cHBV Program AB - 101

  5. Slide 5: HBV: A Global Public Health Threat with a Significant Unmet Medical Need

    Chronic HBV (2M in U.S.) >250M HBV: A Global Public Health Threat with a Significant Unmet Medical Need Treated 7M 3% Diagnosed 32M 13% Sources: https://www.who.int/news - room/fact - sheets/detail/hepatitis - b https://www.hepb.org/what - is - hepatitis - b/what - is - hepb/facts - and - figures/ P

  6. Slide 6: Rationale for a Functional Cure in HBV

    6 © 2025 Arbutus Biopharma, Inc. Rationale for a Functional Cure in HBV Prevent complications of disease progression - HBsAg loss is strongly associated with a reduced risk of long - term adverse clinical outcomes observed among cHBV patients regardless of the presence of cirrhosis. 1, 2, 3 Decrease

  7. Slide 7: 3-Pronged Approach to Therapeutic Success

    Suppress Reduce Boost Viral DNA Viral Antigen - HBsAg Host Immune System Leading to an HBV Functional Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune response 7

  8. Slide 8: Imdusiran RNAi Therapeutic

    8 © 20 25 Arbutus Biopharma, Inc. Imdusiran RNAi Therapeutic

  9. Slide 9: Imdusiran: Key Differentiators

    Imdusiran: Key Differentiators 9 © 2025 Arbutus Biopharma, Inc. Unique Nucleotide Sequence Single trigger targeting all HBV transcripts including HBx from cccDNA and integrated DNA Specific Chemical Modifications Reduces off - target effects but maintains potency and provides durable liver exposure

  10. Slide 10: Phase 2a POC Clinical Trial IM-PROVE I

    Phase 2a POC Clinical Trial Imdusiran in combination with ongoing NA therapy and short courses of Peg - IFN α - 2 a in cHBV patients IM - PROVE I: POC: Proof of Concept Primary objective : evaluate safety and tolerability of imdusiran in combination with Peg - IFN α - 2a in patients with NA - suppre

  11. Slide 11: IM-PROVE I: Imdusiran with Short Courses of IFN Leads to Functional Cure

    IM - PROVE I: Imdusiran with Short Courses of IFN Leads to Functional Cure Data presented at AASLD 2024 *Subject to regulatory approval © 2025 Arbutus Biopharma, Inc. Patients with HBsAg Loss at Key Time Points A2: IDR (4 doses) + NA + IFN 24W N=13 A1: IDR (6 doses) + NA + IFN 24W N=12 Achieved HBsA

  12. Slide 12: IM-PROVE II Phase 2a Clinical Trial

    12 Off Therapy Follow - up (24 - 48 weeks) Group A ( n=20) : VTP - 300 Group B (n=20): VTP - 300 placebo 1 IDR x 4 doses (60mg Q8W) n=40 Weeks IDR x 4 doses (60mg Q8W) n=22 24 Group C: VTP - 300 ± LDN 1 48 24 Weeks 48 Off Therapy Follow - up (24 - 48 weeks) © 2025 Arbutus Biopharma, Inc. Data presen

  13. Slide 13: Imdusiran: Key Takeaways from Clinical Trials to Date

    Imdusiran: Key Takeaways from Clinical Trials to Date Imdusiran provided robust and comparable HBsAg declines (~1.5 - 2.0 log 10 ) regardless of dose, dosing interval, HBeAg or DNA status When combined with a short course of IFN, a 50% functional cure rate was seen in patients with HBsAg <1000 IU/mL

  14. Slide 14: Strategic Collaboration with Qilu

    Strategic Collaboration Exclusive Licensing* and Strategic Partnership Develop, manufacture and commercialize imdusiran in Greater China Imdusiran Upfront payment (received in 2022) $40M Equity investment (received in 2022) $15M Commercialization and milestone payments Up to $245M Tiered royalties o

  15. Slide 15: AB-101 Oral PD-L1 Checkpoint Inhibitor

    15 © 2025 Arbutus Biopharma, Inc. AB - 101 Oral PD - L1 Checkpoint Inhibitor

  16. Slide 16: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation

    AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation PD - 1: Programmed death ligand protein | Abs: Antibodies Currently in a Phase 1a/1b clinical trial Rationale • HBV immune tolerance is a critical driver of cHBV infection • PD - 1:PD - L1 checkpoint axis plays a key role in immune toleriz

  17. Slide 17: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV

    AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV AB - 101 is highly potent and activates HBV specific immune cells from chronic HBV patients AB - 101 reinvigorates HBV - specific cHBV patient T - cells PBMCs N= cells from 9 cHBV patients *p< - 0.05 PBMC: P eripheral Blood Mononuclear Cells

  18. Slide 18: AB-101-001: Phase 1a/1b Clinical Trial with AB-101

    18 © 2025 Arbutus Biopharma, Inc. Part 1: SAD (n=8/cohort – 6:2) 1C: 10 mg 1B: 3 mg 1A: 1 mg Part 2: MAD (n=10/cohort – 8:2) 2A: 10 mg daily x 7 days 2B: 25 mg daily x 7 days† 3A: 10 mg daily x 28d 3B: Dose/interval TBD x 28d AB - 101 - 001: Phase 1a/1b Clinical Trial with AB - 101 Parts 1 & 2 – Hea

  19. Slide 19: LNP Litigation: Update

    LNP Litigation: Update Moderna - Trial date September 24, 2025 (subject to the Court’s availability)* • Markman Hearing occurred February 8, 2024 – judge heard arguments on claim construction. – Court provided ruling on April 3 and agreed with Arbutus’s position on the majority of the claims • Exper

  20. Slide 20: 2025 Key Milestones

    2025 Key Milestones 20 Timing 2025 Milestone 1H Initiate Phase 2b clinical trial (imdusiran + IFN) 1H IM - PROVE II Phase 2a (imdusiran + VTP - 300 + nivolumab): Functional cure data 1H AB - 101 - 001: Preliminary data from Cohort 3A in cHBV patients 1H LNP Litigation: Outcome of PFE Markman Hearing

  21. Slide 21: Investment Highlights

    Investment Highlights Strong financial position Indication with significant unmet medical need & large market opportunities Patented LNP technology Portfolio of internally discovered assets with distinct MOAs Lead HBV compound – imdusiran, RNAi therapeutic advancing into Phase 2b combination clinica

  22. Slide 22: Thank You

    Thank You 22 © 2025 Arbutus Biopharma, Inc.

Arbutus Biopharma — Investor Presentation (January 2025) on 6ix